Digihaler discontinuation may cause new disruption in care for asthma patients

Responding to news that Teva plans to discontinue U.S. distribution of its innovative Digihaler products effective June 1, Asthma and Allergy Foundation of America CEO Ken Mendez says patients currently using Digihalers should start exploring alternatives now. “Unfortunately, when GSK discontinued Flovent, some people using that inhaler may have been transitioned to the ArmonAir Digihaler,” says Mendez, “Because some formularies do not cover the authorized generic of Flovent, the discontinuation of ArmonAir could mean patients are once again searching for an alternative treatment.”